Boehringer Ingelheim Pharmaceuticals, Inc.

Samsung Electronics Co., Ltd.

Boehringer Ingelheim International Gmbh

Beijing Samsung Telecom R&d Center

Chinese Academy of Sciences

Aerie Pharmaceuticals, Inc.

Shionogi Bioresearch Corporation

Lanzhou Institute of of Chemical Physics

Weimin Liu

Eugene R Hickey

Denice Mary Spero

Sanxing Sun

David S Thomson

Yancey David Ward

Tina Marie Morwick

Zhidong Chen

Erick Richard Roush Young

Peter Allen Nemoto

Michel Jose Emmanuel

Todd Bosanac

Lifen Wu

Pui Leng Loke

Stephane De Lombaert

Younes Bekkali

Heather Tye

Usha R Patel

Ho Yin Lo

Erick R R Young

Doris Riether

Renee M Zindell

Ming-Hong Hao

Alessandra Bartolozzi

Charles Lawrence Cywin

Daniel Richard Marshall

John David Ginn

Roman Wolfgang Fleck

Ronald John Sorcek

Leah Lynn Frye

Jiang-Ping Wu

Pengfei Wang

Alan Olague

Jonathon Alan Dines

Jonathan Emillian Emeigh

Erick Richard Young

Qingli Zhang

Guang Yang

Michael Robert Turner

Pier Francesco Cirillo

Thomas Martin Kirrane, Jr

Roger John Snow

Can Mao

Anthony S Prokopowicz

Xiuli Zheng

Darren DiSalvo

Sabine K Schlyer

Frank Wu

Xiaohui Xu

Xiaobo Wang

Ying Gu

Huajun Cao

Cheng-Kon Shih

Eugene Richard Hickey

Jiasheng Wu

Na Li

John Robert Proudfoot

Neil Moss

Hidenori Takahashi

Derek Cogan

Hongyan Zhang

Rene Marc Lemieux

Shuit-Tong Lee

Zhaoming Xiong

Chun-Sing Lee

Donghong Amy Gao

Thomas A Gilmore

Alexander Heim-Riether

Tai-Nang Huang

Steven Richard Brunette

Matt Aaron Tschantz

Craig Andrew Miller

Ming Shen

Bryan Patrick McKibben

Stéphane De Lombaert

Joerg Bentzien

Jennifer A Kowalski

Chuk Chui Man

Rajashehar Betageri

Hui Yu

Joshua Courtney Horan

Bing Li

Yang Yu

Michael David Lawlor

Antonio Jose Del Moral Barbosa, Jr

Gaiqing Zhao

Shijie Zhang

Teresa Przewloka

Guiqing Liang

Jiechao Ge

Singgou Fu

Ho-Yin Lo

Minhuan Lan

An oil-soluble conductive agent and a preparation method therefor. Raw materials for preparing the oil-soluble conductive agent comprise the following components: 20 parts by weight of ethyl caprate or bis(2-ethylhexyl) sebacate, 1.8-2.2 parts by weight of ethyl methyl carbonate, and 2-8 parts by weight of fluorine-containing ion salt; and the fluorine-containing ion salt is selected from one or more of lithium bis(trifluoromethanesulfonyl)imide, lithium trifluoromethanesulfonate, and lithium tetrafluoroborate. The oil-soluble conductive agent is apparently a colorless transparent liquid at 25° C. or higher, and the conductivity at 25° C. reaches 1×10S/cm. The oil-soluble conductive agent can be completely dissolved in a base oil and improve the conductivity thereof, so as to have the effects of arc suppression, being anti-static, cooling, heat transfer, and conduction.

Oil-soluble conductive additive and preparation method therefor

The present invention discloses a hypocrellin derivative substituted both in a pen-position and in a 2-position by an amino, and a preparation method and use thereof. A general structural formula of the derivative is as represented by formulas I-a to I-d:  The hypocrellin derivative substituted both in a peri-position and in a 2-position by an amino prepared in the present invention has a maximum absorption wavelength of 600-650 nm and a molar extinction coefficient reaching about 20000-40000 Mcm. Compared with unmodified hypocrellin or hypocrellin having only a 2-position modified, an absorption spectrum of the derivative is significantly red-shifted and the molar extinction coefficient is greatly improved, and the derivative can efficiently produce reactive oxygen species such as singlet oxygen in a photosensitive condition. In the same condition, the hypocrellin derivative substituted both in a pen-position and in a 2-position by an amino involved in the present invention, when used as a photosensitizer, has a stronger ability to photo-dynamically inactivate tumor cells than the first and second generation commercial photosensitizers.

Hypocrellin derivative substituted both in a peri-position and in 2-position by amino, preparation method, and application thereof

Provided are an electronic device and method for providing content to a user. The method includes, based on text of the user, obtaining content corresponding to the text and being adaptive to the user, wherein the obtained content is adaptive to the user based on information regarding the user, which is collected based on the user's behavior on the electronic device; and providing the obtained content to the user.

Device and method for providing content to user

The invention discloses a monosubstituted or polysubstituted amphiphilic hypocrellin derivative, and a preparation method and application thereof. The amphiphilic hypocrellin derivative substituted by a group containing PEG, a quaternary ammonium salt or the like prepared according to the invention has an obvious red shift in its absorption spectrum and a significantly enhanced molar extinction coefficient, compared with the parent hypocrellin, can efficiently produce singlet state oxygen and other reactive oxygen species under photosensitive conditions; has different amphiphilicities and increased biocompatibility with cells or tissues by regulating its hydrophilicity and hydrophobicity; can meet the requirements of different clinical drugs, and solves the requirements of different drug delivery methods for different drug hydrophilicity and lipophilicity. Under identical conditions, the amphiphilic hypocrellin derivative photosensitizer according to the invention has higher ability to photodynamically inactivate tumor cells than the first and second generation commercial photosensitizers.

Monosubstituted or polysubstituted amphiphilic hypocrellin derivative, and preparation method and application thereof

Provided are an electronic device and method for displaying content. The content corresponds to a point of interest (POI) of a user and is adaptive to the user. The content is acquired based on a user input with regard to the POI, which is displayed.

Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds.

Rho kinase inhibitors

A method for obtaining network feedback is provided by a terminal. The method includes sending data information, publishing, by the terminal, the data information to a website, establishing a correspondence relationship between the data information and the published data information, accessing the website on which the data information is published, and obtaining feedback information to the data information, processing the data information and the feedback information, and informing a user of an updating status of the feedback information. The embodiment of the present disclosure further provides a terminal device for obtaining the network feedback.

Method and device for obtaining network feedback

The present invention relates to compounds of formula (IA) and (IB): and pharmaceutically acceptable salts thereof, wherein R-Rare as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Benzimidazole inhibitors of leukotriene production

Isoquinolinone Rho kinase inhibitors

The present invention relates to compounds of formula (IA), (IB) and (IC): and pharmaceutically acceptable salts thereof, wherein R-Rare as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

The present invention relates to compound of formula (I): or pharmaceutically acceptable salts thereof, wherein R-Rare as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Oxadiazole inhibitors of leukotriene production

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R-Rare as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

The present invention relates to compounds of formula (I) and (IA): and pharmaceutically acceptable salts thereof, wherein R-Rare as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Derivatives of 6,7-dihydro-5H-imidazo[1,2-&#x3b1;]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

Derivatives of 6,7-dihydro-5H-imidazo[1,2-alpha]imidazole-3-carboxylic acid amides

Growing community of inventors

Beijing, China

Weimin Liu